Dry formulation for transcutaneous immunization
CA 2368655 A1 · Owner: Scharton-Kersten, Tanya · Inventors: Glenn, Gregory M.; Scharton-Kersten, Tanya
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A transcutaneous immunization system delivers antigen to immune cells through the skin, and induces an immune response in an animal or human. For example a , skin-active adjuvant (e.g. an ADP-ribosylating exotoxin) can be used to induce an antigen-specific immune response (e.g. humoral and/or cellular effectors) after transcutaneous application of a dry formulation containing antigen and adjuvant to skin of the animal or human. The dry formulation may be a powder or a unit-dose patch. Use of adjuvant is not required if the antigen is sufficiently antigenic. Transcutaneous immunization may be induced with or without penetration enhancement.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed April 10, 2000. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended April 10, 2020.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by April 10, 2022.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.